Mocht u de informatie op onze website waarderen dan wilt u ons misschien ondersteunen met een donatie

Ons rekeningnummer is: RABO t.n.v. Stichting Gezondheid Actueel in Terneuzen. Onze IBANcode is NL79 RABO 0372 9311 38

Als donateur kunt u ook korting krijgen bij verschillende bedrijven. En we hebben een ANBI status

Zie ook in gerelateerde artikelen.

6 september 2019:

Recent is een nieuwe reviewstudie gepubliceerd over het New Castle Disease Virus bij de behandeling van kanker. Auteurs prof. dr. Volker Schirrmacher *, Dr. Stefaan van Gool en Wilfried Stuecker , allen werkzaam in het IOZK - Keulen. Zij werken al jaren met het Newcastle Disease Virus.

Klik op de titel van de studie voor het studierapport in PDF vorm: 

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy

Hier het abstract maar het studierapport is zeer uitgebreid. Zeker de moeite waard dit te lezen. 

Volker Schirrmacher *, Stefaan van Gool and Wilfried Stuecker Immune-Oncological Center Cologne (IOZK), D-50674 Cologne, Germany * Correspondence: Received: 30 July 2019; Accepted: 23 August 2019; Published: 30 August 2019 Abstract: Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus (NDV) as a biological agent with potential to break therapy resistance. This avian virus combines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic effects with 11 described immune stimulatory properties. Fifty years of clinical application of NDV give witness to the high safety profile of this biological agent. In 2015, an important milestone was achieved, namely the successful production of NDV according to Good Manufacturing Practice (GMP). Based on this, IOZK in Cologne, Germany, obtained a GMP certificate for the production of a dendritic cell vaccine loaded with tumor antigens from a lysate of patient-derived tumor cells together with immunological danger signals from NDV for intracutaneous application. This update includes single case reports and retrospective analyses from patients treated at IOZK. The review also presents future perspectives, including the concept of in situ vaccination and the combination of NDV or other oncolytic viruses with checkpoint inhibitors.

10 mei 2011: Lees wel ook dit als u overweegt een consult te doen bij dr. Gorter:  Klik hier of onder vragen voor uitvoerige uitleg waarom wij dr. Robert Gorter geen betrouwbare arts meer vinden. Het Newcastle Disease Virus als behandeling staat wat ons betreft niet ter discussie.

15 april 2012: 

Onderstaande berichtgeving is nog steeds actueel. Het Newcastle Disease Virus en andere virussen worden meer en meer ingezet bij het bestrijden van kanker..  Als u hier klikt kunt u het volledige studierapport gratis inzien van een studie uit 2011. Met de titel: 

1 januari 2005
Onderstaande informatie over het Newcastle Virus kregen we in augustus 2004 van een Duitse arts.


Newcastle disease virus (NDV) was the name given by Doyle to a highly contagious viral infection of poultry, also known as fowl pest, which was first reported on a farm near Newcastle upon Tyne, UK, in 1926. Shortly after the reported disease at Newcastle, two further outbreaks occurred in the UK, one in Somerset and the other in Staffordshire. At about the same time, a disease with similar symptoms was observed in Java (in the capital city now known as Jakarta), Indonesia, and shortly thereafter in other regions of Southeast Asia, notably around seaports of the Indian Ocean. Sub¬sequent cross-immunity tests showed that the viruses isolated in Southeast Asia and Newcastle upon Tyne were indistinguishable. The causative agent of the disease in Newcastle upon Tyne was identified as a virus, which was distinct from fowl plague (avian influenza virus), although the symptoms bore some resemblance. It is thought likely that the virus was transported to the port of Newcastle upon Tyne by ship from Southeast Asia. Whatever its origin, the new disease emerged and rapidly spread throughout the world [1,2,3].

The application of viruses for cancer treatment was based on anecdotal reports since the beginning of the 20th century on tempo¬rary improvement of cancer following natural viral infections or vaccinations against viral diseases, for example, rabies [4]. In 1965, Cassell and Garrett [5] first used live Newcastle disease virus (NDV) deliber¬ately to treat a human cancer, applying it intratumorally on one patient with cervical carcinoma. The application of NDV took importance after 1968 when a poultry farmer suffering from metastatic gastric cancer who had exhibited a spectac¬ular clinical improvement after having been exposed to a NDV poultry epidemic [6]. Following these reports on the anti-neoplastic effect of NDV, a few researchers have employed an attenuated NDV strain, designated MTH-68/H, to treat a variety of human malignancies [6,7].

The virus is a membrane-enveloped virus non-segmented, negative-stranded RNA of roughly spherical structure. It contains a helical nucleocapside structure, with a central hole. The main protein subunit of the nucleocapside is the nucleocapside protein (NP). Two other proteins, the phosphoprotein (P) and the large (L) protein are also associated with the nucleocapside. The envelope is a lipid double layer derived from the host cell plasma membrane and has embedded in it, and protruding from it, the spike glycol-proteins hem agglutinin-neuraminidase (HN) and fusion (F). The matrix protein (M) is interposed between the nucleo¬capside and the viral envelope [1,2,3].
The virus is nonpathogenic to humans, except for rare transient respiratory infection among poultry workers. Some attenuated NDV strains have marked oncolytic properties in human tumors [2]. Attenuated NDV strains have been in use for over 40 years and have shown genetic stability, without anti-genie drift [3]. Following administration, oncolytic NDV strains, like MTH-68/H selectively replicate in human tumor cells, destroying them, whereas non-neoplastic cells remain unaffected [3,8,9,10]. Wild type NDV is the agent of the Newcastle Disease of chicken.

Mechanisms of action against cancerous cells.
Our knowledge of the mechanism of the tumor-destructive action of the oncolytic attenuated NDV strains is still growing. There are two ways, by which viruses can destroy their host cells: (1) by inducing necrosis or lysis by their excessive replication; (2) by inducing programmed cell death, apoptosis [7].

According to pilot studies on the interaction of NDV and tumor cells, both lysis and apoptosis are at work [8,12,13,14]. The apoptotic effect of MTH-68/H has been studied in the PC12 rat pheochromocytoma cell line [8,12]. PC 12 cells were found to be killed by MTH-68/H in a dose-dependent manner. Cell death was accompanied by internucleosomal DNA fragmentation, characteris¬tic of apoptosis. A very brief exposure to MTH-68/H was sufficient to induce full-blown apoptotic response. To induce oncolysis and apoptosis, an accurate targeting of tumor cells by the virus is of crucial importance. NDV envelope glycoproteins attach to sialic acid host cell membrane receptors . Since sialic acid receptors are widely distributed in different cell types, the targeting of NDV to human ectodermal, mesenchymal and neuro-ectodermal tumor cells is understandable . However, it is not sufficiently elu¬cidated why NDV targets selectively neoplastic cells, while normal cells also expressing sialic acid surface receptors remain uninfected. Nevertheless, it becomes increasingly clear that NDV's direct oncolytic and apoptosis-inducing effect is responsible for its clinical effectiveness. The immunomodulatory potency of the live attenuated NDV viral treatment may also play an important adjunctive role.
The beneficial effects and good applicability of live oncolytic attenuated NDV strains such as MTH-68/H are based on three important features:

(1) They selec¬tively target neoplastically transformed cells and leave normal cells uninfected [10,15] and Fabian Z et al., unpublished results)
(2) They are replication competent and destroy their host tumor cells
(3) The attenu¬ated NDV strains are stable, have an extensive safety database, and are well tolerated by patients with mini¬mal, if any, side effects.
MTH-68/H has been employed only once the other classical anti-neoplastic treat¬ments have failed. MTH-68/H proves to be a powerful weapon against the most malignant neuro-ectodermal tumor, Glioblastoma Multiforme, and its application has advantages not only with regard to current chemotherapy, but also to some novel therapeutic approaches. Controlled clinical trials using MTH-68/H are in preparation the efficacy of this virus therapy on a greater number of neuro-oncological and oncological patients.

Application. Application of oncolytic virus therapy to treat human neoplasms has over a three decade history. MTH-68/H, a live attenu¬ated oncolytic viral strain of the Newcastle disease virus, is one of the viruses used in the treatment of different malignancies. With regard to the unfavorable results of con¬ventional modalities in the treatment of human malignancies, novel therapeutic methods were tried as to their potential to inhibit tumor growth. One such method is the use of attenuated viruses to treat human malignancies [16,17,18]. The application of viruses for cancer treatment was based on anecdotal reports on tempo¬rary improvement of cancer following natural viral infections or vaccinations against viral diseases. Cassell and Garrett were the first in use the live Newcastle disease virus (NDV) deliber¬ately to treat a human cancer, applying it intratumorally [5].
The application of NDV took importance after 1968 with a patient who had exhibited a spectac¬ular clinical improvement after having been exposed to NDV poultry epidemic [6]. Following these reports on the antineoplastic effect of NDV, the a few researchers has employed an attenuated NDV strain, designated MTH-68/H, to treat a variety of human malignancies [6,7]. MTH-68/H has been developed into a highly purified, lyophilized product, containing live, replication com¬petent oncolytic viral particles, grown to standardized liters. A Phase II clinical trial using MTH-68/H was completed in 1991, where the inhalatory mode of administration was used, on patients suffering from a variety of advanced malignancies, no longer respon¬sive to conventional treatment modalities. The study demonstrated relative efficacy, an overall improved quality of life, and a benign side effect profile . The oncolytic potential of MTH-68/H has been char¬acterized under tissue culture conditions. MTH-68/H was found to be cytotoxic, as measured by the W cytotoxicity assay, on six tumor cell lines tested :

ƒÍ PC rat pheochromocytoma.
ƒÍ B16 mouse melanoma, Cos.
ƒÍ SV-40-transformed] monkey kidney tumor.
ƒÍ HeLa human cervical carcinoma.
ƒÍ MCF-7 human breast ade-nocarcinoma and 293T.
ƒÍ Adenovirus 5 DNA transformed human kidney cells.
ƒÍ Glioblastoma Multiforme.

Titer-dependence of the cytotoxic effect of MTH-68/H showed differences between these tumor cell lines. Replication of the virus in two of the tumor cell lines has been verified. In contrast, the non-neoplastic NIH3T3 mouse fibroblasts and Rat-1 rat fibroblasts were completely resistant to the cyto-cidal effect of MTH-68/H (Fabian Z and Szeberenyi J, unpublished results). In PC12 cells, a widely used model cell line for differentiation, survival and apoptosis signaling, MTH-68/H induced titer-dependent apoptotic DNA fragmentation [8,12]. The results of these cell culture studies strongly support the notion that MTH-68/H, besides a potential immunostimulatory effect, exerts its anti-cancer action by directly and selectively attacking and killing tumor cells.

Clinical Experience.
Pollak et al. described two cases with radical surgical approach and without recurrence for at least ten years and reviewed similar cases in the literature. Salvati et al. reported on 11 patients with GBM who lived at least 5 years after the diagnosis was first established. Yoshida et al. described two cases of 'decade survivors' after the removal of GBM from the frontal lobe, followed by chemotherapy and radiotherapy of these authors regard the radical surgical removal of the tumor and the relatively young age of the patient as the main factors determining long-term survival.

A special type of GBM, characterized histologically by a marked predominance of bizarre, multinucleated giant cells, represents a specific subgroup distinguished by a more favorable prognosis and long-term survival. Klein et al. reviewed the literature and added a case of a child who survived 11 years after operation until the time of publication. This special subgroup makes up about 5% of the GBMs . Giant cell GBMs form a distinct group according to molecular genetic studies . The question arises as to whether in the previous case reports in the literature, this specific histological type of giant cell GBM was recognized and whether at least part of the cases with long-term survival had not actually belonged to this subgroup.

Gene therapy aims at the introduction of additional genetic material which is transcribed and translated into proteins in the tumor cell and which counteracts uncontrolled prolifer¬ation. As vectors for gene transfer, genetically modified retro viruses, adeno viruses, coxsackie virusses and attenuated herpes sim¬plex virus have been used. As to gliomas, transfection of 'suicide' genes (e.g. herpes simplex virus thymidine kinase), of anti-angiogenic genes, tumor suppressor genes such as p53 andE2F-l, of cell surface receptors and of genes to induce apoptosis (e.g. box) has been in the foreground of research [25,26,27,28].

Therapy with oncolytic viruses is not a new con¬cept, although, there is increasing interest in this treatment modality among oncologists [4,29,30]. Sev¬eral virus strains, including retroviruses, adenoviruses, herpes viruses, parvo- and paramyxoviruses were described to have oncolytic properties [4,31]. Perhaps the most effective clinical experience has been achieved with a paramyxovirus, the attenuated NDV, upon which MTH-68/H treatment is based [6,7].

To investigate the anti-tumor effect of NDV, Xue LJ, found that the strong suppressive effect of NDV on the growth of these tumor cells was effective without dose dependence. They concluded that the NDV might be a potential anti-tumor agent Previously Zaitsev V showed that NDV had a protein called Hemagglutinin Neuraminidasa (HN) contained pliable sialic acid recognition. Presenting evidence of a binding site for its involvement in cell fusion .

Dolganiuc V explored the association of the NDV fusion (F) protein with cholesterol-rich membrane domains, founding that specific localization of the F protein in cholesterol-rich membrane domains is not required for cell-to-cell fusion . In basis of the results of Bar-Eli N, he demonstrates that NDV caused preferential damage to lymphoma cells as compared to non-cancerous normal cells The HN protein of the NDV plays a crucial role in the process of infection, Huang Z, established the hypothesis that the virulence of NDV is multigenic and that the cleavability of F protein alone does not determine the virulence of a strain .

Application of New Castle Disease Virus in the Cologne Model
In the Cologne Model, NCDV has recently been introduced for the treatment of solid tumors. The virus is made in the laboratory of Dendrimun Köln, the laboratory where also autologous dendritic cells, LAK cells, and stem cells for patients, who are being treated in the Medical Center Cologne, are being manufactured.

Patients who are eligible for treatment with NCDV will usually receive NCDV through an intra-arterial catheter to deliver the virus as close to the tumor as possible. For the implantation of intra-arterial catheters, close collaboration has been established with two extremely experienced doctors, specialized in implanting these catheters.

A second form of application is to deliver the NCDV intra-tumorally. Whether an intra-arterial catheter is used or whether the virus is injected directly into the tumor depends on several factors.

The first experiences are very positive and a clinical study is on its way to document efficacy and possible side effects.

1. Emmerson P T, Newcastle disease virus (Paramyxoviridae); Virology and Microbiology; Academic Press. University of newcastle upon tyne, Uk; 1999.
2. Csatary LK, Csatary E, Moss RW: Scientific interest in Newcastle disease virus is reviving. J Natl Cancer Inst 92: 493-494, 2000
3. Lorence RM, Roberts MS, Groene WS, Rabin H:Replication-competent, oncolytic Newcastle disease virusfor cancer therapy. In: Driever PH, Rabkin SD (eds):Replication-Competent Viruses for Cancer Therapy.Monographs in Virology, Vol 22. Doerr HW, Karger, 2001,160-182
4. Szeberenyi J, Fabian Z, Torocsik B, Kiss K, Csatary LK: Newcastle disease virus-induced apoptosis in PC 12 pheochromocytoma cells. Am J Therap 10(4): 282-288, 2003
5. Reichard KW, Lorence RM, Cascino CJ: Selective replica¬tion of Newcastle disease virus (NDV) in cancer cells isassociated with virus-induced cell fusion. Proc Am Assoc Cancer Res 33: 521, 1992
6. Reichard KW, Lorence RM, Cascino CJ, Peeples ME,Walter RJ, Fernando MB, Reyes HM, Greager JA:Newcastle disease virus selectively kills human tumor cells. J Surg Res 52: 448^-53, 1992
7. Fazakerley J, Allsopp TE: Programmed cell death in virus infections of the nervous system. In: Gosztonyi G (ed)The Mechanisms of Neuronal Damage in Virus Infections of the Nervous System. CTMI 253: 95-119 (2001)
8. Fabian Z, Torocsik B, Csatary LK, Kiss K, Szeberenyi J: Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68/H) in PC12 rat phaeochromocytoma cells. Anti-cancer Res 21: 125-136, 2001
9. Reichard KW, Lorence RM, Katubig BB, Peeples ME, Reyes HM: Retinoic acid enhances killing of neuroblastoma cells by Newcastle disease virus. J Pediatr Surg 28:1221-1225, 1993
10. Lam KM, Vasconcelos AC, Bickford AA: Apoptosis as a cause of death in chicken embryos inoculated with Newcastle disease virus. Microb Pathol 19: 169-174, 1995
11. Reichard KW, Lorence RM, Cascino CJ: Selective replica¬tion of Newcastle disease virus (NDV) in cancer cells is associated with virus-induced cell fusion. Proc Am Assoc Cancer Res 33: 521, 1992
12. Webb HE, Gordon Smith CE: Viruses in the treatment of cancer. Lancet 1: 1206-1208, 1970
13. Driever PH, Rabkin SD (eds): Replication-Competent Viruses for Cancer Therapy. Monographs in Virology. Vol 22. Karger, Basel, 2001
14. Nemunaitis J: Live viruses in cancer treatment. Oncology 16: 1483-1492, 2002
15. Nelson NJ: Viruses and cancer. JNatl Cancer Inst 91: 1709, 1999
16. Cassell WA, Garrett RE: Newcastle disease virus as an antineoplastic agent. Cancer 18: 863-868, 1965
17. Csatary LK: Viruses in the treatment of cancer. Lancet 2: 825, 1971
18. Csatary LK, Moss RW, Beuth I, Torocsik B, Szeberenyi J, Bakacs T: Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H).
19. Csatary LK, Eckhardt-S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P, Bodey B, Csatary CM: Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17: 619-627, 1993
20. Pollak L, Gur R, Walach N, Reif R, Tamir L, Schiffer J: Clinical determinants of long-term survival in patients with glioblastoma multiforme. Turnori 83: 613-617, 1997.
21. Salvati M, Cervoni L, Artico M, Caruso R, Gagliardi FM; Long-term survival in patents with supratentorial glioblastoma. J Neuro-Oncol 36: 61-64, 1998
22. Yoshida T, Kawano N, Oka H, Fujii K, Nakazato Y: Clinical cure of glioblastoma - two case reports. Neurol Med Chir (Tokyo) 40: 224-229, 2000
23. Klein R, Molenkamp G, Sorensen N, Roggendorf W: Favor¬ able outcome of giant cell glioblastoma in a child. Report of an 11-year survival period. Childs Nerv Syst 14: 288-291, 1998
24. Meyer-Puttlitz B, Hayashi Y, Wahaa A, Rollbrocker B, Bostrom J, Wiestler OD, Louis DN, Reifenberger G, von Deimling A: Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 151: 853-857, 1997
25. Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP, Fueyo J: Gene therapy for glioblas¬ tomas: Molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252: 1-12, 1999
26. Markert JM, Gillespie GY, Weichselbaum RR, Roizman B, Whitley RJ: Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 10: 17-30, 2000
27. Tunici P, Gianni D, Finocchiaro G: Gene therapy of glioblas¬ tomas: from suicide to homicide. Prog. Brain Res 132: 711-719,2001
28. Karpati G, Li H, Nalbantoglu J: Molecular therapy for glioblastoma. Curr Opin Mol Ther 1: 545-552, 1999 Pennisi E: Training viruses to attack cancers. Science 282: 1244-1246, 1998
29. Pennisi E: Training viruses to attack cancers. Science 282: 1244-1246, 1998
30. Nelson NJ: Scientific interest in Newcastle disease virus is reviving. Viruses and cancer. J Natl Cancer Inst 91: 1708-1710, 1999
31. Fueyo J, Alemany R, Gomez-Marzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG Suzuki K, Sawaya R, Curiel DT, Alfred Yung WK, Lang FF: Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Ntl Cancer Inst 95: 652-660, 2003
32. Xue LJ, Jin NY, Gong W, Wang HW, Sun DH, Luo QF, Ge T, Li P. The Effect of Newcastle disease virus on the biological behavior of tumor cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2003 Jan;19(1):29-31.
33. Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B, Csatary CM. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol. 2004 Mar-Apr;67(1-2):83-93.
34. Zaitsev V, von Itzstein M, Groves D, Kiefel M, Takimoto T, Portner A, Taylor G. Second sialic acid binding site in Newcastle disease virus hemagglutinin-neuraminidase: implications for fusion. J Virol. 2004 Apr;78(7):3733-41.
35. Dolganiuc V, McGinnes L, Luna EJ, Morrison TG. Role of the cytoplasmic domain of the Newcastle disease virus fusion protein in association with lipid rafts. J Virol. 2003 Dec;77(24):12968-7
36. Bar-Eli N, Giloh H, Schlesinger M, Zakay-Rones Z. Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J Cancer Res Clin Oncol. 1996;122(7):409-15.
37. Huang Z, Panda A, Elankumaran S, Govindarajan D, Rockemann DD, Samal SK. The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J Virol. 2004 Apr;78(8):4176-84.


Plaats een reactie ...

Reageer op "Het Newcastle Diasease Virus is nog steeds veelbelovend en actueel als behandeling bij kanker. Lees hier wat het Newcastle Disease Virus is en hoe het wordt gegeven."

Gerelateerde artikelen

Gerelateerde artikelen

Dendritische cellen en Newcastle >> Newcastle Disease Virus lijkt >> Het Newcastle Disease Virus >> Het Newcastle Diasease Virus >> Studie met Newcastle Diasease >> Newcastle Disease Virus, een >>